Tag: hepatocellular carcinoma

1. Combination treatment of atezolizumab and bevacizumab was shown to significantly increase overall survival and progression-free survival outcomes in patients with advanced unresectable hepatocellular carcinoma. 2. Patients treated with the combinatorial treatment of atezolizumab and bevacizumab were shown to experience serious toxic side effects. Evidence Rating Level: 1 (Excellent) Hepatocellular carcinoma is a...
1. Combination treatment of atezolizumab and bevacizumab was shown to significantly increase overall survival and progression-free survival outcomes in patients with advanced unresectable hepatocellular carcinoma. 2. Patients treated with the combinatorial treatment of atezolizumab and bevacizumab were shown to experience serious toxic side effects. Evidence Rating Level: 1 (Excellent) Study Rundown: Hepatocellular...
1. In this prospective propensity score (PS)-matched cohort study, lipophilic statins were found to significantly reduce incidence and mortality of hepatocellular carcinoma (HCC). 2. No significant association was found between use of hydrophilic statins and HCC risk. Evidence Rating Level: 2 (Good) Study Rundown: The mortality for hepatocellular carcinoma is increasing at...
  1. When combined with hepatic artery ligation, the current treatment for hepatocellular carcinoma (HCC), tirapazimine (TPZ) was found to decrease tumor recurrence in mice. 2. TPZ and hepatic artery ligation together led to almost complete necrosis of tumor cells in mice with HCC. Evidence Rating Level: 3 (Average) Study Rundown: Transarterial...
1. This study established a simple, graphically-based prognostic nomogram for overall and progression-free survival in patients with non-metastatic hepatocellular carcinoma following chemoembolization. The model had good discrimination and calibration abilities for both 3- and 5-year survival. Evidence Rating: 2 (Good) Study Rundown: There have been a variety of individual factors...
1. In patients with chronic liver disease, magnetic resonance (MR) imaging was more sensitive than computed tomography (CT) for the diagnosis of hepatocellular carcinoma (HCC) when considered on a per-lesion basis. 2. The sensitivity of both imaging methods was significantly lower among HCCs less than one centimeter in diameter when...
1. In a phase III trial of over 700 patients with hepatocellular carcinoma (HCC), there was no significant difference in overall survival between combination therapy with sorafenib plus erlotinib versus sorafenib plus placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: The annual mortality from hepatocellular carcinoma (HCC) ranges from 250 000...
In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Effect of Erythropoietin and Transfusion Threshold on Neurological Recovery After Traumatic Brain Injury Patients with traumatic brain injury (TBI) commonly develop anemia, which can cause secondary injury and worsen neurological outcomes. Erythropoietin has...
1. Compared to placebo, treatment with everolimus did not improve survival in patients with advanced hepatocellular carcinoma (HCC) who had previously failed sorafenib treatment.  2. Compared to placebo, everolimus treatment did not delay time to disease progression but did improve the disease control rate.  Evidence Rating Level: 1 (Excellent)    ...
1. This systematic review identified very-low strength evidence pertaining to the benefits of screening for hepatocellular carcinoma (HCC) among patients with chronic liver disease. Evidence Rating Level: 1 (Excellent)  Study Rundown: The incidence and mortality of HCC has been increasing, especially among patients with chronic liver disease.   However, the utility of...